LY2275796
- Generic Name
- LY2275796
- Drug Type
- Small Molecule
- Background
LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal NeoplasmsColorectal CarcinomaColorectal Tumors
- Interventions
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01675128
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
LY2275796 in Advanced Cancer
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00903708
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath